What Is Inflammation? What Is Sepsis? What Is MODS?

Evidence-Based Practice of Critical Care

Volumn , Issue , 2011, Pages 151-156

  Patrozou, Eleni ^a   Opal, Steven M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882895801     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5476-4.00024-9     Document Type: Chapter

References (35)

1. Opal S.M. Severe sepsis and septic shock: Defining the clinical problem. Scand J Infect Dis 2003, 35:529-534.
2. Opal S.M., Cross A.S. Clinical trials for severe sepsis: Past failures, and future hopes. Infect Dis Clin North Am 1999, 13:285-297. vii.
3. Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
4. Lee H.K., Iwasaki A. Innate control of adaptive immunity: Dendritic cells and beyond. Semin Immunol 2007, 19:48-55.
5. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002, 111:927-930.
6. Zacharowski K., Zacharowski P.A., Koch A., et al. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci U S A 2006, 103:6392-6397.
7. Beutler B., Hoebe K., Georgel P., et al. Genetic analysis of innate immunity: TIR adapter proteins in innate and adaptive immune responses. Microbes Infect 2004, 6:1374-1381.
8. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
9. Johnson G.B., Brunn G.J., Platt J.L. Cutting edge: An endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004, 172:20-24.
10. Tang A.H., Brunn G.J., Cascalho M., Platt J.L. Pivotal advance: Endogenous pathway to SIRS, sepsis, and related conditions. J Leukoc Biol 2007, 82:282-285.
11. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
12. Opal S.M., DePalo V.A. Anti-inflammatory cytokines. Chest 2000, 117:1162-1172.
13. Matsushima A., Ogura H., Fujita K., et al. Early activation of gammadelta T lymphocytes in patients with severe systemic inflammatory response syndrome. Shock 2004, 22:11-15.
14. Schwacha M.G., Ayala A., Chaudry I.H. Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury. J Leukoc Biol 2000, 67:644-650.
15. Moore T.A., Moore B.B., Newstead M.W., Standiford T.J. Gamma delta-T cells are critical for survival and early proinflammatory cytokine gene expression during murine Klebsiella pneumonia. J Immunol 2000, 165:2643-2650.
16. Emoto M. Are NKT cells essential for endotoxic shock?. Arch Immunol Ther Exp (Warsz) 2003, 51:231-236.
17. Baecher-Allan C., Viglietta V., Hafler D.A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16:89-98.
18. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332:1351-1362.
19. Galon J., Franchimont D., Hiroi N., et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002, 16:61-71.
20. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296.
21. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
22. Pittet D., Rangel-Frausto S., Li N., et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 1995, 21:302-309.
23. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
24. Tran D.D., Groeneveld A.B., van der Meulen J., et al. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med 1990, 18:474-479.
25. Deitch E.A. Multiple organ failure: Pathophysiology and potential future therapy. Ann Surg 1992, 216:117-134.
26. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
27. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
28. Marshall J.C., Cook D.J., Christou N.V., et al. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652.
29. Elbers P.W., Ince C. Mechanisms of critical illness: Classifying microcirculatory flow abnormalities in distributive shock. Crit Care 2006, 10:221.
30. Crouser E.D. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004, 4:729-741.
31. Marshall J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001, 29(suppl 7):S99-S106.
32. Court O., Kumar A., Parrillo J.E. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002, 6:500-508.
33. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
34. Shoemaker W.C., Montgomery E.S., Kaplan E., Elwyn D.H. Physiologic patterns in surviving and nonsurviving shock patients: Use of sequential cardiorespiratory variables in defining criteria for therapeutic goals and early warning of death. Arch Surg 1973, 106:630-636.
35. Poeze M., Ramsay G., Gerlach H., et al. An international sepsis survey: A study of doctors' knowledge and perception about sepsis. Crit Care 2004, 8:R409-413.